Sepsis-related coagulopathy treatment based on the disseminated intravascular coagulation diagnostic criteria: a post-hoc analysis of a prospective multicenter observational study

[1]  N. Takeyama,et al.  Age-related differences in the survival benefit of the administration of antithrombin, recombinant human thrombomodulin, or their combination in sepsis , 2022, Scientific Reports.

[2]  M. Cheng,et al.  Role of international normalized ratio in nonpulmonary sepsis screening: An observational study , 2021, World journal of clinical cases.

[3]  M. Egi,et al.  The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2020 (J-SSCG 2020) , 2021, Journal of Intensive Care.

[4]  H. Yasunaga,et al.  Time Trends of the Outcomes and Treatment Options for Disseminated Intravascular Coagulation: A Nationwide Observational Study in Japan , 2020, JMA journal.

[5]  J. Vincent,et al.  Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy , 2020, Critical care medicine.

[6]  Niranjan Kissoon,et al.  Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study , 2020, The Lancet.

[7]  D. Maucort-Boulch,et al.  A new simplified and accurate sa-SOFA score. , 2019, Journal of critical care.

[8]  N. Takeyama,et al.  Identifying Sepsis Populations Benefitting from Anticoagulant Therapy: A Prospective Cohort Study Incorporating a Restricted Cubic Spline Regression Model , 2019, Thrombosis and Haemostasis.

[9]  H. Okudera,et al.  Role of disseminated intravascular coagulation in severe sepsis. , 2019, Thrombosis research.

[10]  P. Barie,et al.  Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial. , 2019, JAMA.

[11]  T. van der Poll.  Recombinant Human Soluble Thrombomodulin in Patients With Sepsis-Associated Coagulopathy: Another Negative Sepsis Trial? , 2019, JAMA.

[12]  S. Kushimoto,et al.  Diagnosis of sepsis‐induced disseminated intravascular coagulation and coagulopathy , 2019, Acute medicine & surgery.

[13]  H. Okudera,et al.  Characteristics, management, and in-hospital mortality among patients with severe sepsis in intensive care units in Japan: the FORECAST study , 2018, Critical Care.

[14]  M. Kollef,et al.  Sepsis-Associated Coagulopathy Severity Predicts Hospital Mortality* , 2018, Critical care medicine.

[15]  Y. Umemura,et al.  Optimal patient selection for anticoagulant therapy in sepsis: an evidence‐based proposal from Japan , 2018, Journal of thrombosis and haemostasis : JTH.

[16]  J. Thachil,et al.  New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey , 2017, BMJ Open.

[17]  M. Levi,et al.  Disseminated intravascular coagulation , 2016, Nature Reviews Disease Primers.

[18]  Y. Umemura,et al.  Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta‐analysis of randomized controlled trials , 2016, Journal of thrombosis and haemostasis : JTH.

[19]  R. Bellomo,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[20]  F. Meziani,et al.  What’s new in the diagnostic criteria of disseminated intravascular coagulation? , 2016, Intensive Care Medicine.

[21]  T. van der Poll,et al.  A Short Contemporary History of Disseminated Intravascular Coagulation , 2014, Seminars in Thrombosis & Hemostasis.

[22]  Satoshi Gando,et al.  A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis , 2013, Critical Care.

[23]  B. Engelmann,et al.  Thrombosis as an intravascular effector of innate immunity , 2012, Nature Reviews Immunology.

[24]  Andrew Rhodes,et al.  Drotrecogin alfa (activated) in adults with septic shock. , 2012, The New England journal of medicine.

[25]  S. Opal,et al.  Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. , 2011, American journal of respiratory and critical care medicine.

[26]  S. Kushimoto,et al.  Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: Results of a multicenter, prospective survey* , 2008, Critical care medicine.

[27]  Yasuhiro Ohtomo,et al.  A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: Comparing current criteria* , 2006, Critical care medicine.

[28]  R. Rossaint,et al.  Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. , 2005, The New England journal of medicine.

[29]  C. Sprung,et al.  Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. , 2003, JAMA.

[30]  Mitchell M. Levy,et al.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive Care Medicine.

[31]  F B Taylor,et al.  Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation , 2001, Thrombosis and Haemostasis.

[32]  S. Opal,et al.  High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial , 2001 .

[33]  J. Vincent,et al.  Serial evaluation of the SOFA score to predict outcome in critically ill patients. , 2001, JAMA.

[34]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[35]  J. E. Carceller.  American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis , 1992, Critical care medicine.

[36]  R. Bone,et al.  The pathogenesis of sepsis. , 1991, Annals of internal medicine.

[37]  E. Draper,et al.  APACHE II: A severity of disease classification system , 1985, Critical care medicine.

[38]  W. Knaus,et al.  APACHE II: a severity of disease classification system. , 1985 .

[39]  Y. Umemura,et al.  Screening itself for disseminated intravascular coagulation may reduce mortality in sepsis: A nationwide multicenter registry in Japan. , 2018, Thrombosis research.

[40]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[41]  S. Opal,et al.  Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. , 2001, JAMA.

[42]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.